VERTEX PHARMACEUTICALS ($VRTX) posted quarterly earnings results on Monday, May 5th. The company reported earnings of $4.06 per share, missing estimates of $4.41 by $0.35. The company also reported revenue of $2,770,200,000, missing estimates of $2,909,656,488 by $-139,456,488.
You can see Quiver Quantitative's $VRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERTEX PHARMACEUTICALS Insider Trading Activity
VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- RESHMA KEWALRAMANI (CEO & President) sold 15,198 shares for an estimated $7,826,970
- DAVID ALTSHULER (EVP, Chief Scientific Officer) has made 0 purchases and 7 sales selling 12,939 shares for an estimated $6,405,364.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 4 sales selling 7,854 shares for an estimated $3,844,667.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 3 sales selling 6,164 shares for an estimated $2,912,812.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 5,090 shares for an estimated $2,332,768.
- CHARLES F JR WAGNER (EVP & Chief Financial Officer) sold 3,298 shares for an estimated $1,649,000
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 2,931 shares for an estimated $1,363,231.
- SANGEETA N. BHATIA sold 400 shares for an estimated $202,344
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VERTEX PHARMACEUTICALS Hedge Fund Activity
We have seen 746 institutional investors add shares of VERTEX PHARMACEUTICALS stock to their portfolio, and 752 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 3,452,747 shares (-46.8%) from their portfolio in Q4 2024, for an estimated $1,390,421,216
- PARNASSUS INVESTMENTS, LLC added 1,815,950 shares (+inf%) to their portfolio in Q4 2024, for an estimated $731,283,065
- CAPITAL WORLD INVESTORS added 1,514,993 shares (+5.7%) to their portfolio in Q4 2024, for an estimated $610,087,681
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,426,746 shares (+15.8%) to their portfolio in Q4 2024, for an estimated $574,550,614
- EDGEWOOD MANAGEMENT LLC added 1,410,238 shares (+91.2%) to their portfolio in Q4 2024, for an estimated $567,902,842
- FMR LLC removed 1,305,967 shares (-12.4%) from their portfolio in Q4 2024, for an estimated $525,912,910
- WELLINGTON MANAGEMENT GROUP LLP added 1,117,214 shares (+23.3%) to their portfolio in Q4 2024, for an estimated $449,902,077
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VERTEX PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $VRTX stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/20.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 2 purchases worth up to $100,000 on 03/13, 02/24 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
VERTEX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- China Renaissance Securities (US) Inc. issued a "Positive" rating on 02/10/2025
- BMO Capital issued a "Outperform" rating on 01/31/2025
- H.C. Wainwright issued a "Buy" rating on 01/31/2025
- Citigroup issued a "Buy" rating on 11/13/2024
To track analyst ratings and price targets for VERTEX PHARMACEUTICALS, check out Quiver Quantitative's $VRTX forecast page.
VERTEX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 6 analysts offer price targets for $VRTX in the last 6 months, with a median target of $497.5.
Here are some recent targets:
- An analyst from Cantor Fitzgerald set a target price of $535.0 on 04/22/2025
- Evan Seigerman from BMO Capital set a target price of $545.0 on 01/31/2025
- Mohit Bansal from Wells Fargo set a target price of $460.0 on 01/30/2025
- Terence Flynn from Morgan Stanley set a target price of $456.0 on 01/10/2025
- Brian Abrahams from RBC Capital set a target price of $400.0 on 12/19/2024
- Michael Yee from Jefferies set a target price of $550.0 on 12/09/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
